LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants
May 16, 2024 02:00 ET
|
LIfT BioSciences
LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants Groundbreaking in vivo studies will be progressed to explore the impact of IMAN cell...
LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors
December 21, 2023 02:00 ET
|
LIfT BioSciences
LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors London, 21 December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company...
LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy
August 03, 2023 02:00 ET
|
LIfT BioSciences
LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy Positive data supports the potential of the iN-LIfT platform to...
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs
July 06, 2023 07:00 ET
|
LIfT BioSciences
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs
July 06, 2023 02:00 ET
|
LIfT BioSciences
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...
LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids
May 04, 2023 07:00 ET
|
LIfT BioSciences
- IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model - IMAN is the world’s first neutrophil-based cell therapy, generated...
LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids
May 04, 2023 02:00 ET
|
LIfT BioSciences
- IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model - IMAN is the world’s first neutrophil-based cell therapy, generated...
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours
March 21, 2023 08:46 ET
|
LIfT BioSciences
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours
March 21, 2023 03:00 ET
|
LIfT BioSciences
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS
December 19, 2022 07:00 ET
|
LIfT BioSciences
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19...